Special Situation: All Eyes on ABVX
This article presents a long thesis for Abivax (ABVX), a biotech company. The author argues that despite the stock's popularity, the downside risk is limited even if no acquisition occurs. The investment is framed as a special situation with a favorable risk/reward profile.
Automatically collect high-quality investment opinions from across the web daily
Over 50+ high-quality investment ideas await you every day
Investment insights from 15+ platforms like Substack, Seeking Alpha, X/Twitter, with AI-powered summaries, categorized by industry. Register for free to access all features.